The latest price target for Acelyrin (NASDAQ:SLRN) was reported by Citigroup on January 7, 2025. The analyst firm set a price target for $3.00 expecting SLRN to rise to within 12 months (a possible 16.28% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Acelyrin (NASDAQ:SLRN) was provided by Citigroup, and Acelyrin maintained their neutral rating.

The last upgrade for Acelyrin Inc happened on July 8, 2024 when Wells Fargo raised their price target to $13. Wells Fargo previously had an equal-weight for Acelyrin Inc.

The last downgrade for Acelyrin Inc happened on August 15, 2024 when HC Wainwright & Co. changed their price target from $18 to $6 for Acelyrin Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acelyrin, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acelyrin was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.

While ratings are subjective and will change, the latest Acelyrin (SLRN) rating was a maintained with a price target of $6.00 to $3.00. The current price Acelyrin (SLRN) is trading at is $2.58, which is out of the analyst’s predicted range.